Effects of Dexmedetomidine on the Behavioral Outcomes in Streptozotocin‐Induced Alzheimer's Disease Rats
These findings indicate that Dex at 25 µg/kg attenuates STZ-induced cognitive deficits, likely through neuroprotective and anti-inflammatory mechanisms. The results highlight Dex as a promising candidate for AD therapy, though further research is required to elucidate its underlying molecular pathways. The study supports the potential repurposing of Dex for neurodegenerative disorders.
Authors
- Vida Mirzaie (ORCID: https://orcid.org/0000-0001-7052-2013)
- Mohsen Basiri (ORCID: https://orcid.org/0000-0003-2512-7641)
- Masoumeh Baghalishahi (ORCID: https://orcid.org/0000-0002-2240-0262)
- Ali Shamsara
- Mina Mohasel‐Roodi
- Masoumeh Nozari
Institutions
- Kerman University of Medical Sciences (IR)
Publication Details
- Journal
- Brain and Behavior
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/brb3.71196
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kerman University of Medical Sciences